Stem Cell Transplantation
Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.
This fact sheet reviews bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) as they relate to the cancer treatment.
An assessment of depression in patients before autologous or allogeneic HCT demonstrated that the condition impacts overall survival and risk of GVDH in patients with hematologic malignancies.
A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.
Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.
Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.
Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).
Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.
In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.
Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT) significantly prolonged overall survival in patients with multiple myeloma compared with no maintenance, a meta-analysis of 3 randomized controlled trials presented at the 2016 ASCO Annual Meeting has found.
Upfront autologous stem cell transplantation (ASCT) remains the preferred treatment for patients age 65 years or younger with newly diagnosed multiple myeloma, according to phase 3 study results reported at the 2016 ASCO Annual Meeting.
Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical TransplantationApril 25, 2016
Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.
Current presence of pain was associated with both greater depression and fatigue in survivors of hematopoietic stem cell transplantation (HSCT).
Results for patients with acute leukemia that received the antibody showed lower incidence of chronic graft-versus-host disease post-transplant.
For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.
For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.
Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)November 25, 2015
More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.
A sleep deficit of just 4 hours affects the ability of blood and immune-system stem cells to migrate to the proper spots in the bone marrow of recipient mice and churn out the cell types necessary to reconstitute a damaged immune system by as much as 50%.
High-Dose Chemo and Stem Cell Transplantation Results in Long-Term Survival for Patients With AmyloidosisOctober 27, 2015
Patients with light-chain amyloidosis who are treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival.
Targeting exhausted immune cells may change the prognosis for patients with AML relapse after a stem cell transplant, according to a recent study.
Greatly improved outcomes have been observed in using stem cell transplantation to treat patients with juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer.
An experimental new treatment approach could buy patients with a rare and dangerous leukemia type the time to obtain a stem cell transplant.
Younger, unrelated donors with high T cell counts make better matches for patients undergoing stem cell transplantJune 29, 2015
Measuring the T lymphocyte count in stem cell transplant donors can improve matchmaking for patients in need of an allogeneic stem cell transplant.
Lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival, according to findings from a phase 2 clinical trial.
The stress of caregivers of patients receiving stem cell transplantation can be successfully reduced by an intervention, according to a randomized controlled trial.
A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.
Almost half of patients with blood cancer who had relapsed following allogeneic stem cell transplantation benefitted from treatment with the immune checkpoint blocker ipilimumab.
Study shows need for psychosocial support for patients undergoing hematopoietic stem cell transplantDecember 25, 2014
According to a recent study, patients undergoing hematopoietic stem cell transplantation (HCT) reported a steep problems and substantially worsening depression during hospitalization.
A recent study shows that, in the case of stem cell transplantation in a child, parents feel increased distress at the time of the procedure, but eventually recover.
Genetically engineered cell therapies may bring hope to patients for whom standard treatments have been unsuccessful, according to two separate studies presented at the 2013 ASH Annual Meeting, in New Orleans, Louisiana.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|